Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-56418 Sodium in Subjects With Endometriosis

Next Previous
Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-56418 Sodium in Subjects With Endometriosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elagolix (Primary)
  • Indications Dysmenorrhoea; Endometriosis; Pelvic pain
  • Focus Therapeutic Use
  • Acronyms Daisy-PETAL
  • Sponsors Neurocrine Biosciences

Most Recent Events

  • 03 Feb 2012 Actual initiation date changed from Sep 2009 to Aug 2009 as reported by ClinicalTrials.gov.
  • 19 Oct 2011 Abbott Laboratories identified as an additional study sponsor and details added
  • 19 Oct 2011 Results presented at the 67th Annual Meeting of the American Society for Reproductive Medicine.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top